Change history 20 January 2024 A Correction to this paper has been published: References Jonas, J
May 2026: BALANCE Model for Medicaid The Medicaid portion of BALANCE is moving ahead
WHAT IS CAGRILINTIDE Cagrilintide is a synthetic, long-acting amylin analog peptide developed by Novo Nordisk as a potential treatment for obesity and related metabolic conditions
Exclusion criteria included: type 1 diabetes, either acute or chronic pancreatitis, proliferative diabetic retinopathy or macular diabetes, non-proliferative diabetic retinopathy requiring urgent treatment, either acute or chronic hepatopathy with clinic or laboratory evidence of liver injury (e.g., 3-fold elevation in plasmatic transaminases), severe hypoglycemia or unawareness hypoglycemia, gastroparesis, previous bariatric surgery, concomitant use of certain medications delaying gastric emptying, established coronary disease or severe chronic heart failure (NYHA class III or IV), glomerular filtration rate 50%
75 ShuklaT.KhareR.KumarS.LakhwaniD.SharmaD.AsifM